BTIG Research Reiterates “Buy” Rating for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a report released on Friday,Benzinga reports. They currently have a $21.00 target price on the biopharmaceutical company’s stock. BTIG Research’s target price suggests a potential upside of 46.55% from the company’s current price.

TBPH has been the subject of several other research reports. Wall Street Zen downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. HC Wainwright boosted their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Finally, B. Riley Financial restated a “neutral” rating and set a $14.00 price objective (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Theravance Biopharma currently has an average rating of “Moderate Buy” and a consensus target price of $22.60.

Theravance Biopharma Trading Up 2.3%

TBPH stock opened at $14.33 on Friday. Theravance Biopharma has a twelve month low of $7.90 and a twelve month high of $21.03. The company has a market capitalization of $726.10 million, a P/E ratio of 7.06 and a beta of 0.17. The firm has a 50 day simple moving average of $18.00 and a 200-day simple moving average of $16.87.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Wednesday, March 25th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.71. Theravance Biopharma had a net margin of 98.54% and a return on equity of 18.55%. The business had revenue of $45.89 million during the quarter, compared to analyst estimates of $43.09 million. On average, research analysts predict that Theravance Biopharma will post -1.09 EPS for the current year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the sale, the senior vice president directly owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

A number of institutional investors have recently modified their holdings of the business. AQR Capital Management LLC bought a new position in Theravance Biopharma in the first quarter worth about $101,000. Jane Street Group LLC boosted its stake in Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock valued at $1,258,000 after acquiring an additional 88,540 shares during the period. Geode Capital Management LLC grew its holdings in shares of Theravance Biopharma by 0.4% during the second quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company’s stock valued at $9,863,000 after purchasing an additional 3,416 shares during the last quarter. Creative Planning bought a new position in shares of Theravance Biopharma during the second quarter valued at approximately $139,000. Finally, American Century Companies Inc. raised its position in shares of Theravance Biopharma by 6.8% during the 2nd quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock worth $1,009,000 after purchasing an additional 5,794 shares during the period. Institutional investors own 99.10% of the company’s stock.

Trending Headlines about Theravance Biopharma

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company highlights and cash/milestone strength — Theravance reported record brand-level profitability for YUPELRI®, received milestone payments tied to sales, expects ~ $400M in cash at end-Q1 2026 with no debt, and announced cost-reduction targets to generate $60–$70M of annualized cash flow starting Q3 2026. Theravance Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Analyst optimism — BTIG reaffirmed a buy rating and set a $21 price target (material upside from current levels), and Zacks upgraded TBPH to a Rank #1 (Strong Buy), supporting the short-term positive sentiment. Benzinga Zacks: Rating Upgrade to Strong Buy
• Neutral Sentiment: Mixed earnings coverage — company releases show strong non‑GAAP profitability and reported milestone-driven revenue, but media/analytics outlets are publishing differing EPS figures (reports vary between a beat and a miss depending on metric/adjustment). Investors should check the company filing for GAAP vs. non‑GAAP reconciliations. Press Release — Q4 and Full Year 2025 Results Zacks: Q4 Earnings and Revenues Lag Estimates
• Negative Sentiment: Pipeline setback and strategic review — management discontinued ampreloxetine after Phase 3 CYPRESS results, is implementing a restructuring, and has formed a Strategic Review Committee to evaluate options including a potential sale — these actions reduce near-term R&D upside and signal material change in corporate strategy. Zacks: Q4 Earnings and Revenues Miss; Ampreloxetine Scrapped
• Negative Sentiment: Insider selling — SVP Rhonda Farnum sold ~31,067 shares in mid‑March; while not definitive, the sale is being watched by investors as a near-term negative signal. InsiderTrades: SVP Sells Shares

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.